These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 4374291)

  • 1. Letter: neuropathy due to cytosine arabinoside.
    Russell JA; Powles RL
    Br Med J; 1974 Dec; 4(5945):652-3. PubMed ID: 4374291
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
    Saito T; Asai O; Dobashi N; Yano S; Osawa H; Takei Y; Takahara S; Ogasawara Y; Yamaguchi Y; Minami J; Usui N
    J Infect Chemother; 2006 Jun; 12(3):148-51. PubMed ID: 16826348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside.
    Nevill TJ; Benstead TJ; McCormick CW; Hayne OA
    Am J Hematol; 1989 Dec; 32(4):314-5. PubMed ID: 2554727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal peripheral neuropathy associated with axonal degeneration after high-dose cytosine arabinoside in acute leukaemia.
    Paul M; Joshua D; Rahme N; Pollard J; Ell J; Gibson J; Bonnet D
    Br J Haematol; 1991 Nov; 79(3):521-3. PubMed ID: 1661126
    [No Abstract]   [Full Text] [Related]  

  • 5. Central nervous system toxicity with high-dose cytosine arabinoside.
    Herzig RH; Lazarus HM; Herzig GP; Coccia PF; Wolff SN
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):233-6. PubMed ID: 3892703
    [No Abstract]   [Full Text] [Related]  

  • 6. [High doses of cytosine arabinoside in the treatment of refractory leukemia].
    Klener P; Háber J; Kolesková E
    Sb Lek; 1987 Sep; 89(8-9):271-5. PubMed ID: 3478794
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal peripheral neuropathy following FLA chemotherapy.
    Osborne WL; Holyoake TL; McQuaker IG; Parker AN
    Clin Lab Haematol; 2004 Aug; 26(4):295-6. PubMed ID: 15279668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Painful legs and moving toes. Neuropathy caused by cytarabine].
    Malapert D; Degos JD
    Rev Neurol (Paris); 1989; 145(12):869-71. PubMed ID: 2559449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system toxicity of high-dose cytosine arabinoside.
    Barnett MJ; Richards MA; Ganesan TS; Waxman JH; Smith BF; Butler MG; Rohatiner AZ; Slevin ML; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):227-32. PubMed ID: 3925559
    [No Abstract]   [Full Text] [Related]  

  • 10. [Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes].
    Avilés A; Tripp F; Velásquez A; Rubio ME; González-Llavén J
    Rev Invest Clin; 1988; 40(1):21-4. PubMed ID: 3165541
    [No Abstract]   [Full Text] [Related]  

  • 11. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
    Powell BL; Capizzi RL; Lyerly ES; Cooper MR
    J Clin Oncol; 1986 Jan; 4(1):95-7. PubMed ID: 3001234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
    Takaku F; Urabe A; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):144-9. PubMed ID: 3859929
    [No Abstract]   [Full Text] [Related]  

  • 13. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia.
    Openshaw H; Slatkin NE; Stein AS; Hinton DR; Forman SJ
    Cancer; 1996 Nov; 78(9):1899-905. PubMed ID: 8909309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged infusion of arabinosyl cytosine in childhood leukemia.
    Wang JJ; Selawry OS; Vietti TJ; Bodey GP
    Cancer; 1970 Jan; 25(1):1-6. PubMed ID: 5262259
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
    Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN
    Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral neuropathy associated with high-dose Ara-C therapy.
    Borgeat A; De Muralt B; Stalder M
    Cancer; 1986 Aug; 58(4):852-4. PubMed ID: 3013396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
    Altundag O; Altundag K; Celik I; Turker A; Kars A
    Am J Hematol; 2004 Apr; 75(4):263-4. PubMed ID: 15054828
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
    Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.